Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2 Inhibitor
COX-2-IN-24 is an orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 0.17 μM. This compound exhibits significant anti-inflammatory properties while demonstrating low ulcerogenic activities, making it suitable for research on inflammatory diseases and pain management. Its selective inhibition of COX-2 provides valuable insights into the mechanisms of inflammation and the development of therapeutic strategies. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
COX Inhibitor
Timegadine hydrochloride is a selective inhibitor of cyclooxygenase (COX) and lipoxygenase, playing a significant role in inflammatory processes. It demonstrates potent COX inhibition in washed rabbit platelets and rat brain, with IC50 values of 5 nM and 20 μM, respectively. Additionally, Timegadine hydrochloride effectively inhibits lipoxygenase in equine and washed rabbit platelets with an IC50 of 100 μM. This compound is of interest for research applications focusing on anti-arthritis activity and other inflammatory conditions. -
COX-2 Inhibitor
RS-57067 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an inhibition constant (Ki) of 16.9 μM. By effectively reducing the production of prostaglandins, including PGE2, it mitigates inflammatory responses. This compound is suitable for research applications focused on inflammatory and immune-related diseases. -
COX-2 Inhibitor
BMS-347070 is a selective inhibitor of cyclooxygenase-2 (COX-2), primarily involved in inflammatory processes. This compound exhibits significant anti-inflammatory activity and is valuable in research aimed at understanding COX-2’s role in various diseases. Additionally, BMS-347070 can be utilized in studies on Pluronic®-based nano-crystalline drug-polymer solid dispersions for improved drug delivery applications. -
COX Inhibitor
Lobuprofen is a potent COX inhibitor that selectively targets cyclooxygenases (COX-1 and COX-2). It demonstrates significant anti-inflammatory and analgesic effects, making it suitable for research into neurological disorders and related pathologies. This compound can help elucidate the role of inflammation in the progression of neurological diseases and facilitate the development of therapeutic strategies. -
Anti-Inflammatory Agent
M-5011 is a potent orally active anti-inflammatory agent that targets the modulation of inflammatory pathways. This compound exhibits significant antinociceptive effects, demonstrated by its inhibition of kaolin-induced writhing in experimental models. Additionally, M-5011 effectively reduces peritoneal levels of 6-keto-PGF1 alpha while exhibiting low ulcerogenic potential. Its pharmacological profile includes notable anti-inflammatory, anti-pyretic, and analgesic properties, making it valuable for research into pain and inflammation mechanisms. -
Anti-inflammatory Effect, Antioxidant Activity
Prifelone is a di-tert-butylphenol known for its anti-inflammatory effects and antioxidant activity. It demonstrates the ability to inhibit guinea pig lung oxygenase and bovine seminal vesicle cyclooxygenase, making it a valuable tool for research into inflammatory processes and oxidative stress. Its applications include investigations into inflammation-related diseases and the development of therapeutic strategies targeting these pathways. -
COX-2 Inhibitor
COX-2-IN-38 is a potent inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 value of 79.4 nM. This compound effectively modulates inflammatory processes by selectively blocking COX-2 activity, making it a valuable tool for research focused on inflammation and pain management. Its application in various biological assays can aid in the investigation of COX-2-related pathways and the development of anti-inflammatory therapies. -
COX-2 Inhibitor
Ataquimast free base is a selective COX-2 inhibitor that effectively reduces the production of leukotrienes, tumor necrosis factor-alpha (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is primarily utilized in research focused on advanced estrogen receptor-positive breast cancer, making it valuable for studies examining the inflammatory response and tumor progression in this context. -
COX Inhibitor
4',5-Dihydroxy Diclofenac-13C6 is a deuterated derivative of Diclofenac, functioning primarily as a cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory activity, making it useful for studying the mechanisms of inflammation and pain management. Its isotopic labeling allows for advanced analytical techniques in pharmacokinetic studies and metabolic research. -
COX-2 Inhibitor
Indomethacin N-octyl amide is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 of 40 nM. This compound exhibits greater than 1000-fold selectivity over COX-1, with an IC50 of 66 µM. Its potent COX-2 inhibitory activity makes Indomethacin N-octyl amide a valuable tool for research into inflammation and pain pathways. -
COX Inhibitor
AL-8417 ((2R)-AL-5898) is a potent inhibitor of Cyclooxygenase (COX), exhibiting an IC50 of 120 μM. This compound is significant in modulating inflammatory responses, making it a valuable tool for research into pain relief and inflammation management. Its application in experimental settings can further elucidate the role of COX in various biological processes and disease states. -
COX-2 Inhibitor
N-Caffeoyl serotonin is a selective COX-2 inhibitor, characterized by IC50 and Kᵢ values of 42.5 μM and 65.5 μM, respectively. This compound exhibits minimal inhibitory activity against BACE1, with an IC50 greater than 400 μM, and demonstrates free radical scavenging properties. N-Caffeoyl serotonin is pertinent for research in allergic diseases as well as Alzheimer's disease, providing a valuable tool for investigating inflammatory pathways and neurodegeneration. -
COX-2 Inhibitor
Harmaline analog is a selective inhibitor of cyclooxygenase-2 (COX-2) demonstrating an IC50 of 0.145 μM. This compound is useful for studying the COX-2 enzyme's role in inflammatory processes and pain modulation. Its application includes research on anti-inflammatory therapies and the development of novel analgesics. -
Anti-Inflammatory Agent
BF389 is an orally active anti-inflammatory agent that functions as an inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating IC50 values of 4 µg/mL for COX-1 and 8 µg/mL for COX-2. This compound exhibits significant anti-inflammatory activity making it suitable for research in arthritis and other inflammatory conditions. BF389 may serve as a valuable tool in the investigation of therapeutic strategies targeting inflammation-related pathways. -
COX-2 Inhibitor
COX-2-IN-36 is a highly selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 value of 0.4 μM. This compound effectively inhibits COX-2 enzymatic activity, thereby reducing the synthesis of prostaglandins involved in inflammation and pain. It is suitable for research applications focusing on inflammatory diseases, pain management, and cancer biology, offering a valuable tool for exploring COX-2-related pathways. -
COX Inhibitor
N-(3-Pyridyl)indomethacinamide is a COX-2 inhibitor derived from indomethacin. This compound exhibits potent anti-inflammatory activity by selectively inhibiting cyclooxygenase-2, making it valuable for research in inflammation and pain management. Its unique chemical structure allows for further exploration of its effects in various biological systems and therapeutic applications. -
COX-1/2 Inhibitor
COX-1/2-IN-6 is a potent dual inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), exhibiting IC50 values of 68 nM and 91 nM, respectively. This compound is valuable for studying inflammatory diseases by effectively modulating the COX enzymatic pathways involved in prostaglandin synthesis. Its inhibition profile makes it suitable for research on pain management and inflammatory-related conditions. -
COX-1 Inhibitor
Tenidap sodium is a selective inhibitor of cyclooxygenase-1 (COX-1), with an IC50 of 0.03 μM for COX-1 and 1.2 μM for COX-2. This non-steroidal anti-inflammatory compound exhibits significant anti-inflammatory and anti-rheumatic properties, making it valuable in research focused on inflammatory diseases. Additionally, Tenidap functions as a specific inhibitor of SLC26A3, further broadening its potential applications in biochemical studies. -
COX-2 Inhibitor
4-Desmethyl-2-methyl celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, exhibiting an IC50 value of 0.069 µM. This compound demonstrates significant anti-inflammatory, analgesic, and antipyretic properties by reducing the synthesis of prostaglandins. Its efficacy makes it a valuable tool for the investigation of inflammatory conditions and pain-related disorders, including rheumatoid arthritis and osteoarthritis. -
COX-2 Inhibitor
ABT-963 is a selective inhibitor of cyclooxygenase-2 (COX-2), targeting the COX-2 enzyme involved in the biosynthesis of prostaglandins. This compound exhibits significant anti-inflammatory and analgesic properties, making it a valuable tool for research focused on pain mechanisms and inflammatory diseases. ABT-963 can be utilized to explore the role of COX-2 in various pathophysiological processes, facilitating the development of therapeutic strategies for related conditions. -
COX-2 Inhibitor
Methosulide is a selective COX-2 inhibitor, exhibiting an IC50 value of 2.31 μM. This compound is primarily utilized in the study of inflammatory diseases, providing insights into the role of COX-2 in various pathological conditions. Its selective inhibition profile makes it a valuable tool for researchers investigating potential therapeutic strategies targeting inflammatory pathways. -
COX/5-LOX Inhibitor
ZLJ-6 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating potent oral bioactivity. With IC50 values of 0.73 μM for COX-1, 0.31 μM for COX-2, and 0.99 μM for 5-LOX, ZLJ-6 exhibits significant anti-inflammatory and analgesic properties. This compound is suitable for research applications aimed at investigating inflammatory pathways and potential therapeutic interventions. -
COX Inhibitor
Flosulide is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant anti-inflammatory properties. It effectively reduces inflammation and alleviates pain associated with various inflammatory diseases. Flosulide is commonly used in research applications focused on the modulation of inflammatory pathways and exploration of COX-2 related biological processes. -
COX-2 Inhibitor
COX-2-IN-39 is a highly effective inhibitor of cyclooxygenase-2 (COX-2), demonstrating an impressive IC50 value of 0.4 nM. This compound plays a critical role in research focused on inflammation and pain pathways, making it a valuable tool for studying COX-2-related diseases and therapeutic interventions. Its potency allows for precise modulation of COX-2 activity in various experimental models, facilitating in-depth analysis of its biological effects. -
Non-steroidal Anti-inflammatory Reagent
Piketoprofen is a non-steroidal anti-inflammatory agent primarily targeting the cyclooxygenase-2 (COX-2) enzyme. It exhibits significant analgesic and anti-inflammatory activity, making it suitable for research applications related to soft tissue rheumatism. Piketoprofen-amide, a prodrug form, offers enhanced delivery and efficacy in COX-2 inhibition, providing valuable insights into therapeutic strategies for inflammatory conditions. -
COX Inhibitor
Catechin hydrate is a potent inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 1.4 μM. Its anti-inflammatory properties make it valuable in research applications related to pain relief and inflammatory disease models. This compound's capability to modulate COX-1 activity supports studies investigating the biochemical pathways involved in inflammation and related conditions. -
5-LOX/COX Inhibitor
(-)-Bornyl ferulate serves as a dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), displaying IC50 values of 10.4 μM and 12.0 μM, respectively. This compound demonstrates significant anti-inflammatory potential, making it useful for research focused on inflammation-related pathways and conditions. Its ability to modulate leukotriene and prostaglandin synthesis positions it as a valuable tool in the study of various inflammatory diseases and therapeutic interventions. -
COX-2 Inhibitor
Cavidine is a selective COX-2 inhibitor that exhibits potent anti-inflammatory properties. It is particularly useful in research concerning skin injuries, hepatitis, cholecystitis, and scabies. Additionally, Cavidine has been shown to alleviate LPS-induced acute lung injury through modulation of the NF-κB signaling pathway, making it a valuable compound for studying inflammation-related conditions. -
COX-2 Inhibitor
Nimesulide-d5 is a deuterated form of Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor. It demonstrates a time-dependent inhibitory effect on COX-2 with IC50 values ranging from 70 nM to 70 μM, while exhibiting negligible activity on COX-1 (IC50 >100 μM). Nimesulide-d5 is utilized in research applications focusing on inflammatory processes, pain management, and antipyretic effects, supporting studies aimed at understanding COX-2 mediated pathways. -
COX Inhibitor
Piroxicam olamine is a non-steroidal anti-inflammatory drug that acts as an inhibitor of cyclooxygenase (COX), targeting both COX-1 and COX-2 isoforms with IC50 values of 47 μM and 25 μM, respectively, in human monocytes. This compound is primarily used in research applications focused on inflammation and analgesia. Its mechanism of action makes it a valuable tool for studying pathways involved in pain and inflammatory responses. -
Non-steroidal Anti-inflammatory Agent
Ketoprofen sodium is a non-steroidal anti-inflammatory agent that primarily targets cyclooxygenase (COX) enzymes, demonstrating inhibitory activity with IC50 values of 2 nM for COX-1 and 26 nM for COX-2. This compound is valuable in the study of inflammatory processes, immunological responses, and metabolic disorders, including obesity. Its potent anti-inflammatory properties make it a relevant tool in research aimed at understanding and mitigating these conditions. -
COX Inhibitor
COX-2-IN-1 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 3.9 μM. This compound is valuable for studying COX-2-related pathways and has applications in inflammation and pain research. By selectively targeting COX-2, it allows for the investigation of its role in various physiological and pathological processes. -
COX Inhibitor
Tilmacoxib is a highly selective, irreversible inhibitor of human COX-2, demonstrating time-dependent inhibition with an IC50 of 85 nM in enzyme assays. This compound is primarily utilized in studies investigating the role of COX-2 in inflammatory processes and related disease models. Its specificity and potency make it a valuable tool for elucidating the therapeutic potential of COX-2 inhibition in various biological contexts. -
COX Inhibitor
COX/5-LO-IN-1 is a potent inhibitor targeting cyclooxygenase (COX) and 5-lipoxygenase (5-LO), integral enzymes in the arachidonic acid pathway. This compound demonstrates significant anti-inflammatory and anti-allergic properties, making it a valuable tool for investigating the molecular mechanisms underlying inflammatory and allergic diseases. Its dual inhibition profile supports research into therapeutic strategies for various pathological conditions linked to dysregulated eicosanoid signaling. -
COX Inhibitor
SC58451 is a selective inhibitor of cyclooxygenase-2 (COX-2), known for its potency in downregulating inflammatory pathways. By specifically targeting COX-2, this compound is effective in reducing prostaglandin synthesis, making it valuable for studies related to inflammation and pain management. SC58451 is suitable for research applications in understanding diseases where COX-2 plays a critical role, such as cancer and inflammatory disorders. -
CTLA-4/PD-L1 Inhibitor
Davoceticept is a fusion protein consisting of the CD80 (1-107) fragment linked to IGHG1 Fc via a peptidyl linker, targeting CTLA-4 and PD-L1. This variant CD80 vIgD-Fc acts as an immune checkpoint inhibitor, enhancing T cell activation and promoting anti-tumor responses. Its applications include cancer immunotherapy and studying immune modulation in various malignancies, making it a valuable tool for researchers investigating therapeutic strategies in cancer treatment. -
Anti-CTLA4 Antibody
KD6001 is a humanized IgG1κ monoclonal antibody that targets CTLA-4, effectively disrupting the interactions between CTLA-4 and its ligands CD80 and CD86, with an IC50 of 16 ng/mL. This antibody promotes the activation of T cells by enhancing the expression of IL-2 and IFNγ in PHA-activated human lymphocytes. KD6001 demonstrates significant antitumor activity, inhibiting tumor growth in various mouse models, including MC38, B16, and Hepa1-6. It is relevant for research applications in cancer, particularly in advanced melanoma, hepatocellular carcinoma, and liver cancer. -
Calcineurin Inhibitor
Cyclosporin A-Derivative 1 (Free base) acts as a potent calcineurin inhibitor through its interaction with cyclophilin. This compound is derived from cyclosporin A and plays a critical role in immunosuppression by inhibiting T-lymphocyte activation. It is primarily utilized in research applications focused on transplant immunology and autoimmune disease modeling. -
Cyclosporin A Derivative
Cyclosporin A-Derivative 2 is a novel derivative of cyclosporin A known for its immunosuppressive properties. It exerts its effects by binding to cyclophilin, thereby inhibiting the activity of calcineurin. This compound is primarily utilized in research related to transplantation, autoimmune disorders, and T-cell activation. Its unique properties may facilitate studies aimed at understanding immune modulation and therapeutic interventions in related diseases. -
CypD Inhibitor
CypD-IN-4 is a potent and selective inhibitor of cyclophilin D (CypD), exhibiting high affinity with an IC50 of 0.057 μM. This compound is valuable in researching various conditions related to oxidative stress, neurodegenerative diseases, liver dysfunction, aging processes, autophagy, and diabetes. CypD-IN-4 facilitates the exploration of CypD's role in these pathologies, providing insights into potential therapeutic strategies. -
CypD Inhibitor
CypD-IN-3 is a potent and selective inhibitor of cyclophilin D (CypD), demonstrating high affinity with an IC50 value of 0.01 μM. This compound is valuable for studying a range of biological processes and diseases, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes. Its specificity towards CypD makes it an important tool for elucidating the role of this target in various cellular functions and pathological conditions. -
CypE Inhibitor
CypE-IN-1 is a highly potent and selective inhibitor of cyclophilin E (CypE), exhibiting an IC50 of 0.013 μM and a Ki value of 0.072 μM. This compound is valuable for investigating the role of CypE in various pathological conditions, including oxidative stress, neurodegenerative diseases, liver disorders, aging processes, autophagy, and diabetes. Researchers can utilize CypE-IN-1 to explore therapeutic strategies targeting CypE-related pathways. -
Cyclophilin Inhibitor
CypD-IN-29 is a selective inhibitor of Cyclophilin D (CypD), with a key dissociation constant (KD) of 88.2 nM. By targeting CypD, this compound interferes with its interaction with β-amyloid protein in mitochondrial environments, thereby mitigating the formation of mitochondrial permeability transition pores (mPTP). CypD-IN-29 is suited for research focused on Alzheimer's disease mechanisms and mitochondrial dysfunction in neuronal cells. -
Cyclophilin J Inhibitor
ZX-J-19j is a selective inhibitor of cyclophilin J, a crucial target involved in various cellular processes. This compound exhibits potent antitumor activity, making it a valuable tool for cancer research. Its ability to modulate cyclophilin J function provides insights into tumor biology and potential therapeutic pathways. -
Cyclosporin A Crystalline Intermediate
Cyclosporin A-Derivative 1 is a crystalline intermediate of cyclosporin A that functions primarily by inhibiting calcineurin through binding to cyclophilin. This compound exhibits significant immunosuppressive activity, making it valuable in research related to transplantation, autoimmune diseases, and T-cell signaling. Its utility in studying the mechanisms of immune modulation further enhances its relevance in pharmacological investigations. -
FAP-binding peptide
Rofapitide tetraxetan is a highly selective fibroblast activation protein (FAP)-binding peptide, exhibiting a mean IC50 of 2.7 nM for FAP binding. This compound demonstrates significant antitumor activity and can be effectively labeled with radionuclides for use in diagnostic imaging. Its specific targeting of FAP makes it a valuable tool for research applications in cancer diagnosis and therapy. -
FAP Tracer
FAPI-46 is a quinoline-based tracer that selectively targets fibroblast activation protein (FAP). Labeled with radioactive isotopes like 68Ga or 177Lu, FAPI-46 is utilized for tumor imaging across various cancer types. Its high tumor uptake and prolonged tumor accumulation make it a valuable tool for assessing tumor burden and progression in clinical and research settings. -
FAP Inhibitor
UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP), exhibiting an IC50 of 3.2 nM. In addition to FAP inhibition, UAMC-1110 also affects prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM. This compound is primarily utilized in research applications targeting tumor microenvironment modulation and fibroblast-related pathologies.
